{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:52:43Z","timestamp":1780487563409,"version":"3.54.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["E1572-P"],"award-info":[{"award-number":["E1572-P"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["E1697-R"],"award-info":[{"award-number":["E1697-R"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["E3207-R"],"award-info":[{"award-number":["E3207-R"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["E6910-R"],"award-info":[{"award-number":["E6910-R"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["E9275-L"],"award-info":[{"award-number":["E9275-L"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["RX001311"],"award-info":[{"award-number":["RX001311"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["18POST33960192"],"award-info":[{"award-number":["18POST33960192"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL118313"],"award-info":[{"award-number":["R01 HL118313"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R56 AG057584"],"award-info":[{"award-number":["R56 AG057584"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 HL139451"],"award-info":[{"award-number":["T32 HL139451"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["autonomicneuroscience.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autonomic Neuroscience"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.autneu.2021.102834","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T09:35:28Z","timestamp":1624527328000},"page":"102834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Sympathoinhibitory effect of sacubitril-valsartan in heart failure with reduced ejection fraction: A pilot study"],"prefix":"10.1016","volume":"235","author":[{"given":"Kanokwan","family":"Bunsawat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ratchford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy K.","family":"Alpenglow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Stehlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell S.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Walter","family":"Wray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autneu.2021.102834_bb0005","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/01.CIR.99.14.1810","article-title":"Effect of atrial natriuretic peptide on muscle sympathetic activity and its reflex control in human heart failure","volume":"99","author":"Abramson","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.autneu.2021.102834_bb0010","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1161\/01.HYP.26.6.1160","article-title":"Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin","volume":"26","author":"Ando","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.autneu.2021.102834_bb0015","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/hc4301.098282","article-title":"Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity","volume":"104","author":"Azevedo","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.autneu.2021.102834_bb0020","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ijcard.2008.03.056","article-title":"Increased muscle sympathetic nerve activity predicts mortality in heart failure patients","volume":"135","author":"Barretto","year":"2009","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.autneu.2021.102834_bb0025","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0735-1097(01)01172-X","article-title":"Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects","volume":"37","author":"Brunner-La Rocca","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.autneu.2021.102834_bb0030","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1152\/japplphysiol.00454.2020","article-title":"Sacubitril-valsartan improves conduit vessel function and functional capacity, and reduces inflammation in heart failure with reduced ejection fraction","volume":"130","author":"Bunsawat","year":"2021","journal-title":"J. Appl. Physiol. (1985)"},{"key":"10.1016\/j.autneu.2021.102834_bb0035","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(05)77712-6","article-title":"Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators","volume":"351","author":"Cleland","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.autneu.2021.102834_bb0040","doi-asserted-by":"crossref","first-page":"9J","DOI":"10.1016\/S0002-9149(97)00832-1","article-title":"The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease","volume":"80","author":"Cody","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.autneu.2021.102834_bb0045","first-page":"1796","article-title":"Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure","volume":"46","author":"Cohen-Solal","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.autneu.2021.102834_bb0050","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cardfail.2004.03.006","article-title":"Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients","volume":"10","author":"De Matos","year":"2004","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.autneu.2021.102834_bb0055","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/ajh\/hpt032","article-title":"High muscle sympathetic nerve activity is associated with left ventricular dysfunction in treated hypertensive patients","volume":"26","author":"de Souza","year":"2013","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.autneu.2021.102834_bb0060","first-page":"H930","article-title":"Beta-adrenoceptor downregulation in pacing-induced heart failure is associated with increased interstitial NE content","volume":"266","author":"Delehanty","year":"1994","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.autneu.2021.102834_bb0065","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1748-1716.1972.tb05157.x","article-title":"General characteristics of sympathetic activity in human muscle nerves","volume":"84","author":"Delius","year":"1972","journal-title":"Acta Physiol. Scand."},{"key":"10.1016\/j.autneu.2021.102834_bb0070","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1097\/HJH.0000000000001498","article-title":"Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy: final 43-month study report","volume":"35","author":"Dell\u2019Oro","year":"2017","journal-title":"J. Hypertens."},{"key":"10.1016\/j.autneu.2021.102834_bb0075","doi-asserted-by":"crossref","first-page":"H377","DOI":"10.1152\/ajpheart.00289.2012","article-title":"Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure","volume":"303","author":"Deo","year":"2012","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.autneu.2021.102834_bb0080","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6030\/1939-067X-3.1.8","article-title":"Clinical trial structures","volume":"3","author":"Evans","year":"2010","journal-title":"J. Exp. Stroke Transl. Med."},{"key":"10.1016\/j.autneu.2021.102834_bb0085","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40265-019-01181-2","article-title":"Sacubitril\/valsartan: updates and clinical evidence for a disease-modifying approach","volume":"79","author":"Fabris","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.autneu.2021.102834_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autneu.2017.03.005","article-title":"The role of the autonomic nervous system in arrhythmias and sudden cardiac death","volume":"205","author":"Franciosi","year":"2017","journal-title":"Auton. Neurosci."},{"key":"10.1016\/j.autneu.2021.102834_bb0095","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1177\/1535370219861283","article-title":"LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis","volume":"244","author":"Ge","year":"2019","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.autneu.2021.102834_bb0100","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1161\/01.CIR.92.11.3206","article-title":"Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure","volume":"92","author":"Grassi","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.autneu.2021.102834_bb0105","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1097\/HJH.0000000000002093","article-title":"Sympathetic neural overdrive in congestive heart failure and its correlates: systematic reviews and meta-analysis","volume":"37","author":"Grassi","year":"2019","journal-title":"J. Hypertens."},{"key":"10.1016\/j.autneu.2021.102834_bb0110","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijcard.2020.07.027","article-title":"Sympathomodulation in congestive heart failure: from drugs to devices","volume":"321","author":"Grassi","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.autneu.2021.102834_bb0115","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/1074248419872958","article-title":"Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: real-world experience from Taiwan","volume":"25","author":"Hsiao","year":"2020","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.autneu.2021.102834_bb0120","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.autneu.2014.01.004","article-title":"Sympathetic nervous system and inflammation: a conceptual view","volume":"182","author":"Janig","year":"2014","journal-title":"Auton. Neurosci."},{"key":"10.1016\/j.autneu.2021.102834_bb0125","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"Jama"},{"key":"10.1016\/j.autneu.2021.102834_bb0130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jjcc.2008.09.016","article-title":"Augmented sympathoinhibitory effect of valsartan when added to angiotensin-converting enzyme inhibitor in patients with left ventricular dysfunction","volume":"53","author":"Kawamura","year":"2009","journal-title":"J. Cardiol."},{"key":"10.1016\/j.autneu.2021.102834_bb0135","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/HYPERTENSIONAHA.120.15208","article-title":"Influence of sex and age on muscle sympathetic nerve activity of healthy normotensive adults","volume":"76","author":"Keir","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.autneu.2021.102834_bb0140","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1097\/01.ASN.0000098687.01005.A5","article-title":"Sympathetic nerve activity is inappropriately increased in chronic renal disease","volume":"14","author":"Klein","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.autneu.2021.102834_bb0145","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/1755-5922.12183","article-title":"Pharmacodynamic and pharmacokinetic profiles of sacubitril\/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction","volume":"34","author":"Kobalava","year":"2016","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.autneu.2021.102834_bb0150","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00004872-200103001-00015","article-title":"Atrial natriuretic peptide augments the variability of sympathetic nerve activity in human heart failure","volume":"19","author":"Kubo","year":"2001","journal-title":"J. Hypertens."},{"key":"10.1016\/j.autneu.2021.102834_bb0155","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/ajh\/hpv015","article-title":"LCZ696, angiotensin II receptor-neprilysin inhibitor, ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone","volume":"28","author":"Kusaka","year":"2015","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.autneu.2021.102834_bb0160","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1161\/HYPERTENSIONAHA.118.11676","article-title":"Obesity-associated organ damage and sympathetic nervous activity","volume":"73","author":"Lambert","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.autneu.2021.102834_bb0165","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40256-018-0280-5","article-title":"Focused treatment of heart failure with reduced ejection fraction using sacubitril\/valsartan","volume":"18","author":"Liu","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.autneu.2021.102834_bb0170","doi-asserted-by":"crossref","first-page":"236S","DOI":"10.1016\/S0895-7061(97)00329-4","article-title":"Treatment of heart failure with fosinopril: an angiotensin converting enzyme inhibitor with a dual and compensatory route of excretion","volume":"10","author":"Mancia","year":"1997","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.autneu.2021.102834_bb0175","first-page":"R690","article-title":"Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans","volume":"261","author":"Matsukawa","year":"1991","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.autneu.2021.102834_bb0180","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.autneu.2021.102834_bb0185","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-63801-2","article-title":"Clinical and echocardiographic benefit of sacubitril\/valsartan in a real-world population with HF with reduced ejection fraction","volume":"10","author":"Polito","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.autneu.2021.102834_bb0190","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1042\/CS20120437","article-title":"Do high doses of AT(1)-receptor blockers attenuate central sympathetic outflow in humans with chronic heart failure?","volume":"124","author":"Ruzicka","year":"2013","journal-title":"Clin. Sci."},{"key":"10.1016\/j.autneu.2021.102834_bb0195","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10741-018-9757-1","article-title":"Practical guidance on the use of sacubitril\/valsartan for heart failure","volume":"24","author":"Sauer","year":"2019","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.autneu.2021.102834_bb0200","first-page":"529","article-title":"Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19","volume":"38","author":"Sciascia","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.autneu.2021.102834_bb0205","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/HJH.0000000000000567","article-title":"Sympathetic nerve traffic and baroreflex function in optimal, normal, and high-normal blood pressure states","volume":"33","author":"Seravalle","year":"2015","journal-title":"J. Hypertens."},{"key":"10.1016\/j.autneu.2021.102834_bb0210","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/HJH.0000000000001856","article-title":"Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fraction","volume":"37","author":"Seravalle","year":"2019","journal-title":"J. Hypertens."},{"key":"10.1016\/j.autneu.2021.102834_bb0215","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/ejhf.921","article-title":"The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology","volume":"19","author":"van Bilsen","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.autneu.2021.102834_bb0220","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","article-title":"Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study","volume":"69","author":"Williams","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.autneu.2021.102834_bb0225","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1067\/mhj.2001.112783","article-title":"Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy\u2014clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography","volume":"141","author":"Yamazaki","year":"2001","journal-title":"Am. Heart J."},{"key":"10.1016\/j.autneu.2021.102834_bb0230","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.autneu.2021.102834_bb0235","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5444-4","article-title":"A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9\u201311 year-old girls and boys - clinical protocol","volume":"19","author":"Zeng","year":"2019","journal-title":"BMC Cancer"}],"container-title":["Autonomic Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1566070221000643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1566070221000643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:18:19Z","timestamp":1761567499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1566070221000643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":47,"alternative-id":["S1566070221000643"],"URL":"https:\/\/doi.org\/10.1016\/j.autneu.2021.102834","relation":{},"ISSN":["1566-0702"],"issn-type":[{"value":"1566-0702","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sympathoinhibitory effect of sacubitril-valsartan in heart failure with reduced ejection fraction: A pilot study","name":"articletitle","label":"Article Title"},{"value":"Autonomic Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autneu.2021.102834","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102834"}}